Co-Diagnostics (CODX) Highlights 2024 Earnings and Strategic Developments

Author's Avatar
Mar 27, 2025
Article's Main Image

Co-Diagnostics, Inc. (CODX, Financial) detailed its financial performance and strategic initiatives during its 2024 earnings call. The company reported a net loss of $37.6 million on reduced revenues of $3.9 million, down from $6.8 million the previous year. Despite these declines, gross profit slightly rose to $2.9 million. CEO Dwight Egan emphasized advancements in their PCR platform and the expansion of manufacturing capabilities in Utah and India. Future plans include resubmitting an improved FDA 510(k) application for their COVID-19 test and conducting clinical evaluations for tuberculosis and HPV tests in India and South Africa by late 2025.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.